ClinicalTrials.gg
RecruitingNCT06812078Updated Jul 15, 2026

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

A Phase 2 interventional study of TAK-360 and Placebo in Idiopathic Hypersomnia, sponsored by Takeda. Recruiting at 29 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
15th of 27
96 · median 100
Started
2025
with 4 others
Phase 2
10 of 30
3 open now
Primary completion
2026-11
later than 2 of 12 live
Registered
24th of 30
by date
Lead sponsor
2 of 30
Takeda

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 15th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 24th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake.

The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that.

Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

03

Conditions studied

  • Idiopathic Hypersomnia

Browse trials for

Keywords

  • Idiopathic Hypersomnia
  • TAK-360
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. The participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) [inclusive].
  2. The participant has a documented, current diagnosis of IH.

Key Exclusion Criteria:

  1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) [other than IH].
  2. The participant has medically significant thyroid disease.
  3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ [such as basal cell carcinoma] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor.)
  4. The participant has any of the following viral infections based on a positive test result: surface antigen (at screening), virus antibody (at screening), (HIV) antibody/antigen (at screening).
  5. The participant has a history of head injury or head trauma.
  6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
  7. The participant has a history of cerebral ischemia, (less than [\<]5 years from screening), intracranial aneurysm, or arteriovenous malformation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    TAK-360

    Participants will receive TAK-360 tablets, orally, for 4 weeks.

    Drug: TAK-360

  • Placebo comparator
    Placebo

    Participants will receive TAK-360 matching placebo tablets, orally, for 4 weeks.

    Other: Placebo

Interventions

  • TAK-360 tablet.

  • OtherPlacebo

    TAK-360 matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

    Time frame: Up to Week 8

Secondary outcomes

  1. Change from Baseline at Week 4 in Epworth Sleepiness Scale (ESS) Total Score

    The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.

    Time frame: Baseline, Week 4

  2. Change from Baseline at Week 4 in Idiopathic Hypersomnia Severity Scale (IHSS) Total Score

    IHSS is a 14-item self-assessment questionnaire, to measure the severity, frequency and functional impact of the three key IH symptoms (during a recall period of "past 7 days"). The IHSS includes 14 items in total; two items (1 and 2) on nighttime sleep duration and quality, three items (3, 4 and 5) on sleep inertia and sleep drunkenness after nighttime sleep and one (8) after daytime nap, and three items (6, 7 and 9) on diurnal symptoms (nap occurrence, daytime sleepiness). Items 10 to 14 assess daytime functioning alterations due to hypersomnolence. Six items are scored on a 3-point Likert scale and eight items on a 4-point Likert scale; the Likert scale is a point scale which is used to allow the individual to express how much they agree or disagree with a particular statement. The total IHSS score is the sum of all item scores (range: 0 to 50), and higher scores indicate more severe symptoms.

    Time frame: Baseline, Week 4

07

Study locations

28 of 29 sites recruiting
  • Takeda Site 11
    Redwood City, California 94063, United States
    Recruiting
  • Takeda Site 10
    Santa Ana, California 92705, United States
    Recruiting
  • Takeda Site 27
    Colorado Springs, Colorado 80918, United States
    Recruiting
  • Takeda Site 19
    Brandon, Florida 33511, United States
    Recruiting
  • Takeda Site 14
    Winter Park, Florida 32789, United States
    Recruiting
  • Takeda Site 29
    St Louis, Missouri 63123, United States
    Recruiting
  • Takeda Site 16
    Denver, North Carolina 28037, United States
    Recruiting
  • Takeda Site 15
    Huntersville, North Carolina 28078-5082, United States
    Recruiting
  • Takeda Site 12
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Takeda Site 17
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Takeda Site 13
    Columbia, South Carolina 29201, United States
    Recruiting
  • Takeda Site 18
    San Antonio, Texas 78229, United States
    Recruiting
  • Takeda Site 28
    Norfolk, Virginia 23507, United States
    Recruiting
  • Takeda Site 1
    Montpellier, Hrault, France
    Recruiting
  • Takeda Site 3
    Nantes, Pays de Loire 44093, France
    Recruiting
  • Takeda Site 2
    Paris, 75013, France
    Recruiting
  • Takeda Site 4
    Shatin, Hong Kong
    Withdrawn

    Not enrolling at this site — choose another above.

  • Takeda Site 6
    Pozzilli, Isernia, Italy
    Recruiting
  • Takeda Site 7
    Rome, Roma 00133, Italy
    Recruiting
  • Takeda Site 26
    Verona, Veneto, Italy
    Recruiting
  • Takeda Site 5
    Bologna, 40139, Italy
    Recruiting
  • Takeda Site 25
    Fukuoka-Shi Hakata-Ku, Fukuoka 812-0025, Japan
    Recruiting
  • Takeda Site 23
    Kurume-shi, Fukuoka 830-0011, Japan
    Recruiting
  • Takeda Site 22
    Kohoku-ku, Yokohama-Shi, Kanagawa 222-0033, Japan
    Recruiting
  • Takeda Site 20
    Kumamoto, Kumamoto 862-0954, Japan
    Recruiting
  • Takeda Site 21
    Yodogawa-ku, Osaka-shi, Osaka 532-0003, Japan
    Recruiting
  • Takeda Site 24
    Bunkyo-ku, Tokyo 112-0012, Japan
    Recruiting
  • Takeda Site 9
    Vitoria-Gasteiz, Alava 1004, Spain
    Recruiting
  • Takeda Site 8
    Madrid, 28043, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 6, 2025
StartActual
Feb 7, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06812078
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Feb 7, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-360

Start the discussion